GALNT1

Across TCGA pan-cancer cohorts, GALNT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GALNT1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GALNT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GALNT1 expression acts as an unfavorable survival marker.

CCRCC, LSCC, and PDAC are the cancer types where GALNT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.625	1.000	.002	32	view →
LSCC	DFS	Tertile	All	0.887	0.999	.006	8	view →
PDAC	DFS	Tertile	All	0.314	0.488	.033	5	view →
LUAD	OS	Quartile	II,III,IV	0.485	0.863	.039	5	view →
GBM	DFS	Quartile	All	0.756	0.879	.027	2	view →
HNSC	DFS	Tertile	III,IV	0.541	0.771	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GALNT1–CCRCC (OS)

Open the CCRCC breakdown →